T1	Participants 869 946	Women, aged 18-34 years, with no contraindications to the use of combined OCs
T2	Participants 597 620	oral contraceptive (OC)
T3	Participants 1676 1740	Of 47 women randomized, 45 completed the study (CVR: 23; OC: 22)
